LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Clinical Trials and Coronavirus

30/04/2020
BLOG

<Clinical Trials and Coronavirus

Check out the latest news on coronavirus clinical trials.

In a true show of European solidarity in the fight against COVID-19, a French coordinated pan-European clinical trial began this week.

Called 'Discovery', the trial is led by Dr. Florence Ader, an infectious disease specialist in the Infectious and Tropical Diseases Department of Croix-Rousse Hospital in Lyon. The WHO announced a global clinical trial last week - 'Solidarity', which will focus on a select number of medicines in fighting COVID-19: remdesivir, lopinavir and ritonavir, and chloroquine and hydroxychloroquine.

Discovery is a complimentary add-on clinical trial to Solidarity conducted at the European level and coordinated by INSERM, the French National Institute of Health and Medical Research. While the French aspect of the study will be funded by the Ministries of Higher Education, Research and Innovation, the European parts are funded by the public-private partnerships COMBACTE, PREPARE, and the EU-funded project RECOVER.

In France, some 800 patients will take part in the Discovery trial, while 3200 patients in total will be recruited from across Spain, Germany, the Benelux, and the United Kingdom – not even Brexit can stand in the way of European solidarity in the current climate.

Guidance on conducting clinical trials was released last week offering advice on how to deal with extraordinary situations which the coronavirus pandemic presents, as well as specific advice on trials for COVID-19 treatments. The guidance is available here.

EuropaBio and our members remain committed to aiding the fight against COVID-19. Only by working together will we succeed.

Sources:
• https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments
• https://www.aa.com.tr/en/europe/clinical-trial-starts-in-france-for-treating-covid-19/1775935
• https://presse.inserm.fr/lancement-dun-essai-clinique-europeen-contre-le-covid-19/38737/
• https://www.raps.org/news-and-articles/news-articles/2020/3/ema-offers-guidance-on-conducting-trials-during-th

Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.